Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1991-2-14
pubmed:abstractText
The effect of administration of cyclosporin A (CyA) or the novel macrolide FK506 was investigated in AO rats given DA blood transfusions. CyA (10 mg/kg, orally) or FK506 (1 mg/kg, intramuscularly) administered for 14 days from the time of transfusion effectively inhibited primary anti-MHC class I alloantibody production. This profound inhibitory effect persisted throughout the 2-month investigation period, with little increase in 'secondary' alloantibody production following a challenge injection 28 days after drug withdrawal. Flow cytometric analysis revealed no significant differences in the absolute numbers of W3/25+ (CD4+), OX-8+ (CD8+) or OX-12+ (B lymphocytes), in either the spleen or peripheral blood of transfused compared with normal, untreated animals. However, a small but significant increase in the numbers of splenocytes expressing the activation marker OX-40 (activated CD4+ cells) was observed in transfused animals. Either CyA or FK506 significantly reduced the number of cells expressing OX-39 (interleukin-2 receptors) and OX-40. Treatment of transfused animals with CyA, but not FK506 for 14 days resulted in minor, transient reduction in peripheral blood OX-19+ and W3/25+ cells, while 'sparing' the OX-8+ cells; these changes were not observed in spleens. In contrast, the absolute spleen cell numbers of OX-19+, W3/25+ and OX-8+ cells were significantly reduced in transfused animals given 14 days of FK506 treatment, while the corresponding blood cells were unaffected. Induction of splenic lymphoproliferative responses by the T cell mitogen concanavalin A remained normal in animals receiving transfusion alone or with CyA. In contrast, profound inhibition of mitogenic responses was observed in FK506-treated animals and this inhibitory effect declined gradually following drug withdrawal. No non-specific suppressor cell activity was detected in the spleens of rats given transfusion alone or in CyA or FK506-treated transfused animals.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-1689226, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-1689886, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-1689892, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-1689914, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-1690915, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2445077, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2445722, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2447688, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2447689, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2447690, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2456627, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2460401, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2465593, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2472451, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2473767, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2478846, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2523106, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-2523107, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-3349644, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-3485563, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-6448588, http://linkedlifedata.com/resource/pubmed/commentcorrection/1702375-7015629
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0009-9104
pubmed:author
pubmed:issnType
Print
pubmed:volume
82
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
462-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:1702375-Animals, pubmed-meshheading:1702375-Anti-Bacterial Agents, pubmed-meshheading:1702375-Antigens, CD4, pubmed-meshheading:1702375-Antigens, CD8, pubmed-meshheading:1702375-Antigens, Differentiation, T-Lymphocyte, pubmed-meshheading:1702375-B-Lymphocytes, pubmed-meshheading:1702375-Blood Transfusion, pubmed-meshheading:1702375-Cyclosporins, pubmed-meshheading:1702375-Female, pubmed-meshheading:1702375-Histocompatibility Antigens Class II, pubmed-meshheading:1702375-Immunosuppressive Agents, pubmed-meshheading:1702375-Isoantibodies, pubmed-meshheading:1702375-Lymphocyte Activation, pubmed-meshheading:1702375-Rats, pubmed-meshheading:1702375-Rats, Inbred Strains, pubmed-meshheading:1702375-Receptors, Interleukin-2, pubmed-meshheading:1702375-Spleen, pubmed-meshheading:1702375-Tacrolimus
pubmed:year
1990
pubmed:articleTitle
Influence of FK506 and cyclosporin A on alloantibody production and lymphocyte activation following blood transfusion.
pubmed:affiliation
Department of Pathology, University of Aberdeen, Scotland.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't